Which biotechs are the least efficient?

SmartTrend has looked at the biotech industry to determine which companies are the least efficient. Using revenue per employee (RPE)--a ratio useful when comparing a company against others in its industry--SmartTrend found the five public companies that have the lowest efficiency relative to the size of their workforce. As is the case for many biotechs, these companies have little or no revenue but have spent million of dollars--and multiple years--moving drugs through the clinical trials...

MannKind looks to raise $110M

Inhaled diabetes drug developer MannKind hopes to raise as much as $110 million by lending 9 million shares of its stock to Merrill Lynch, a Bank of America holding, at $5.55 a share. Merrill Lynch will then short the stock, giving MannKind additional funding support R&D costs, and for general corporate purposes. MannKind's stock dipped on news of the stock sale....

FDA accepts Mannkind’s response, sets PDUFA date

The FDA has accepted MannKind's resubmission of its NDA for the inhaled insulin drug Afrezza and set a PDUFA action date of December 29, 2010. The much-watched Afrezza NDA received a complete response letter from the FDA in March. At that time the agency requested more information related to several areas of the NDA, including updated safety data related and additional clinical data that support the clinical utility of Afrezza. Regulators also wanted data about the device Mannkind...